PDCD1 and cancer: Immune checkpoint inhibition (ICI) blocking the PD1–PDL1 (programmed cell death protein-1 and its ligand) axis has improved outcomes for several advanced cancers over the past decade but have failed in HGG, including those which acquire secondary hypermutation as a result of previous therapy (10).